article · International Journal of Advanced Research
Background:-Metastatic renal cell carcinoma (mRCC) has undergone major therapeutic advances with the introduction of tyrosine kinase inhibitors (TKIs) and, more recently, immune checkpoint inhibitor based combinations. However, real world data from North Africa remain limited. Objective:-To describe the epidemiological, clinicopathological, and therapeutic characteristics of patients with mRCC and to identify prognostic factors associated with survival. Methods:-We conducted a retrospective, single center study including consecutive patients diagnosed with histologically confirmed mRCC between January 2016 and June 2023. Overall survival (OS) and progression free survival (PFS) were estimated using the Kaplan Meier method. Prognostic factors were explored using univariate and multivariate analyses with a Cox proportional hazards model.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21474/ijar01/23273
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
